Literature DB >> 28830827

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Nicholas J Taylor1, Nandita Mitra2, Alisa M Goldstein3, Margaret A Tucker3, Marie-Françoise Avril4, Esther Azizi5, Wilma Bergman6, D Timothy Bishop7, Brigitte Bressac-de Paillerets8, William Bruno9, Donato Calista10, Lisa A Cannon-Albright11, Francisco Cuellar12, Anne E Cust13, Florence Demenais14, David E Elder15, Anne-Marie Gerdes16, Paola Ghiorzo7, Thais C Grazziotin17, Johan Hansson18, Mark Harland7, Nicholas K Hayward19, Marko Hocevar20, Veronica Höiom18, Christian Ingvar21, Maria Teresa Landi3, Gilles Landman22, Alejandra Larre-Borges23, Sancy A Leachman24, Graham J Mann25, Eduardo Nagore26, Håkan Olsson21, Jane M Palmer19, Barbara Perić20, Dace Pjanova27, Antonia Pritchard19, Susana Puig12, Nienke van der Stoep6, Karin A W Wadt16, Linda Whitaker7, Xiaohong R Yang3, Julia A Newton Bishop7, Nelleke A Gruis6, Peter A Kanetsky28.   

Abstract

Germline mutations in CDKN2A are frequently identified among melanoma kindreds and are associated with increased atypical nevus counts. However, a clear relationship between pathogenic CDKN2A mutation carriage and other nevus phenotypes including counts of common acquired nevi has not yet been established. Using data from GenoMEL, we investigated the relationships between CDKN2A mutation carriage and 2-mm, 5-mm, and atypical nevus counts among blood-related members of melanoma families. Compared with individuals without a pathogenic mutation, those who carried one had an overall higher prevalence of atypical (odds ratio = 1.64; 95% confidence interval = 1.18-2.28) nevi but not 2-mm nevi (odds ratio = 1.06; 95% confidence interval = 0.92-1.21) or 5-mm nevi (odds ratio = 1.26; 95% confidence interval = 0.94-1.70). Stratification by case status showed more pronounced positive associations among non-case family members, who were nearly three times (odds ratio = 2.91; 95% confidence interval = 1.75-4.82) as likely to exhibit nevus counts at or above the median in all three nevus categories simultaneously when harboring a pathogenic mutation (vs. not harboring one). Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28830827      PMCID: PMC5701856          DOI: 10.1016/j.jid.2017.07.829

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  28 in total

1.  Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.

Authors:  Henry T Lynch; Randall E Brand; David Hogg; Carolyn A Deters; Ramon M Fusaro; Jane F Lynch; Ling Liu; Joseph Knezetic; Norman J Lassam; Michael Goggins; Scott Kern
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

2.  An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele.

Authors:  Chandra G Bertram; Rupert M Gaut; Jennifer H Barrett; Elizabeth Pinney; Linda Whitaker; Faye Turner; Veronique Bataille; Isabel Dos Santos Silva; Anthony J Swerdlow; D Timothy Bishop; Julia A Newton Bishop
Journal:  J Invest Dermatol       Date:  2002-10       Impact factor: 8.551

Review 3.  Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium.

Authors:  R F Kefford; J A Newton Bishop; W Bergman; M A Tucker
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

4.  Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.

Authors:  A M Goldstein; J P Struewing; A Chidambaram; M C Fraser; M A Tucker
Journal:  J Natl Cancer Inst       Date:  2000-06-21       Impact factor: 13.506

5.  Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.

Authors:  Stephen J Rulyak; Teresa A Brentnall; Henry T Lynch; Melissa A Austin
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

6.  Longitudinal assessment of the nevus phenotype in a melanoma kindred.

Authors:  Scott R Florell; Laurence J Meyer; Kenneth M Boucher; Patricia A Porter-Gill; Marybeth Hart; Jennica Erickson; Lisa A Cannon-Albright; Lynn K Pershing; Ronald M Harris; Wolfram E Samlowski; John J Zone; Sancy A Leachman
Journal:  J Invest Dermatol       Date:  2004-09       Impact factor: 8.551

7.  Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families.

Authors:  Femke A de Snoo; Jouke-Jan Hottenga; Elizabeth M Gillanders; Loudewijk A Sandkuijl; Mary Pat Jones; Wilma Bergman; Clasine van der Drift; Inge van Leeuwen; Lenny van Mourik; Jeanet A C Ter Huurne; Rune R Frants; Rein Willemze; Martijn H Breuning; Jeffrey M Trent; Nelleke A Gruis
Journal:  Eur J Hum Genet       Date:  2008-04-09       Impact factor: 4.246

8.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).

Authors:  Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop
Journal:  Eur J Cancer       Date:  2008-04-03       Impact factor: 9.162

9.  The Genetic Evolution of Melanoma from Precursor Lesions.

Authors:  A Hunter Shain; Iwei Yeh; Ivanka Kovalyshyn; Aravindhan Sriharan; Eric Talevich; Alexander Gagnon; Reinhard Dummer; Jeffrey North; Laura Pincus; Beth Ruben; William Rickaby; Corrado D'Arrigo; Alistair Robson; Boris C Bastian
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

10.  Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi.

Authors:  Mario Falchi; Veronique Bataille; Nicholas K Hayward; David L Duffy; Julia A Newton Bishop; Tomi Pastinen; Alessandra Cervino; Zhen Z Zhao; Panos Deloukas; Nicole Soranzo; David E Elder; Jennifer H Barrett; Nicholas G Martin; D Timothy Bishop; Grant W Montgomery; Timothy D Spector
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

View more
  11 in total

1.  Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

Authors:  Nicholas J Taylor; Nandita Mitra; Lu Qian; Marie-Françoise Avril; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Francisco Cuellar; Anne E Cust; Florence Demenais; David E Elder; Anne-Marie Gerdes; Paola Ghiorzo; Alisa M Goldstein; Thais C Grazziotin; Nelleke A Gruis; Johan Hansson; Mark Harland; Nicholas K Hayward; Marko Hocevar; Veronica Höiom; Elizabeth A Holland; Christian Ingvar; Maria Teresa Landi; Gilles Landman; Alejandra Larre-Borges; Graham J Mann; Eduardo Nagore; Håkan Olsson; Jane M Palmer; Barbara Perić; Dace Pjanova; Antonia L Pritchard; Susana Puig; Helen Schmid; Nienke van der Stoep; Margaret A Tucker; Karin A W Wadt; Xiaohong R Yang; Julia A Newton-Bishop; Peter A Kanetsky
Journal:  J Am Acad Dermatol       Date:  2019-02-05       Impact factor: 11.527

Review 2.  The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.

Authors:  Hirokazu Kimura; Alison P Klein; Ralph H Hruban; Nicholas J Roberts
Journal:  Pancreas       Date:  2021-09-01       Impact factor: 3.243

3.  POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.

Authors:  M Potrony; J A Puig-Butille; M Ribera-Sola; V Iyer; C D Robles-Espinoza; P Aguilera; C Carrera; J Malvehy; C Badenas; M T Landi; D J Adams; S Puig
Journal:  Br J Dermatol       Date:  2019-02-27       Impact factor: 9.302

Review 4.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

5.  Host Characteristics and Risk of Incident Melanoma by Breslow Thickness.

Authors:  Wen-Qing Li; Eunyoung Cho; Shaowei Wu; Suyun Li; Natalie H Matthews; Abrar A Qureshi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-19       Impact factor: 4.254

Review 6.  Melanoma Genomics.

Authors:  Julia Newton-Bishop; D Timothy Bishop; Mark Harland
Journal:  Acta Derm Venereol       Date:  2020-06-03       Impact factor: 3.875

Review 7.  It's Not All Sunshine: Non-sun-related Melanoma Risk-factors.

Authors:  Veronique Bataille
Journal:  Acta Derm Venereol       Date:  2020-06-03       Impact factor: 3.875

Review 8.  The pivotal role of DNA methylation in the radio-sensitivity of tumor radiotherapy.

Authors:  Xueru Zhu; Yiting Wang; Li Tan; Xiaolong Fu
Journal:  Cancer Med       Date:  2018-06-27       Impact factor: 4.452

Review 9.  CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.

Authors:  Sock Hoai Chan; Jianbang Chiang; Joanne Ngeow
Journal:  Hered Cancer Clin Pract       Date:  2021-03-25       Impact factor: 2.857

10.  Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family.

Authors:  Raffaele Palmirotta; Domenica Lovero; Luigia Stefania Stucci; Erica Silvestris; Davide Quaresmini; Angela Cardascia; Franco Silvestris
Journal:  Int J Mol Sci       Date:  2018-01-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.